471 related articles for article (PubMed ID: 16849428)
1. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.
Szotek PP; Pieretti-Vanmarcke R; Masiakos PT; Dinulescu DM; Connolly D; Foster R; Dombkowski D; Preffer F; Maclaughlin DT; Donahoe PK
Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11154-9. PubMed ID: 16849428
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of the characteristics of side population cells in the human ovarian cancer cell line OVCAR-3].
Luo LJ; Zhao Z; Zeng JF; Liang B; Yang JX; Cao DY; Shen K
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):281-5. PubMed ID: 22781115
[TBL] [Abstract][Full Text] [Related]
3. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
[TBL] [Abstract][Full Text] [Related]
4. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
Pieretti-Vanmarcke R; Donahoe PK; Pearsall LA; Dinulescu DM; Connolly DC; Halpern EF; Seiden MV; MacLaughlin DT
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17426-31. PubMed ID: 17088539
[TBL] [Abstract][Full Text] [Related]
5. Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.
Stephen AE; Pearsall LA; Christian BP; Donahoe PK; Vacanti JP; MacLaughlin DT
Clin Cancer Res; 2002 Aug; 8(8):2640-6. PubMed ID: 12171896
[TBL] [Abstract][Full Text] [Related]
6. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
7. Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics.
Wei X; Dombkowski D; Meirelles K; Pieretti-Vanmarcke R; Szotek PP; Chang HL; Preffer FI; Mueller PR; Teixeira J; MacLaughlin DT; Donahoe PK
Proc Natl Acad Sci U S A; 2010 Nov; 107(44):18874-9. PubMed ID: 20952655
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
9. AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.
Pépin D; Sosulski A; Zhang L; Wang D; Vathipadiekal V; Hendren K; Coletti CM; Yu A; Castro CM; Birrer MJ; Gao G; Donahoe PK
Proc Natl Acad Sci U S A; 2015 Aug; 112(32):E4418-27. PubMed ID: 26216943
[TBL] [Abstract][Full Text] [Related]
10. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.
Wallen JW; Cate RL; Kiefer DM; Riemen MW; Martinez D; Hoffman RM; Donahoe PK; Von Hoff DD; Pepinsky B; Oliff A
Cancer Res; 1989 Apr; 49(8):2005-11. PubMed ID: 2702642
[TBL] [Abstract][Full Text] [Related]
11. Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo.
Stephen AE; Masiakos PT; Segev DL; Vacanti JP; Donahoe PK; MacLaughlin DT
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3214-9. PubMed ID: 11248058
[TBL] [Abstract][Full Text] [Related]
12. Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.
Renaud EJ; MacLaughlin DT; Oliva E; Rueda BR; Donahoe PK
Proc Natl Acad Sci U S A; 2005 Jan; 102(1):111-6. PubMed ID: 15618407
[TBL] [Abstract][Full Text] [Related]
13. Mullerian-inhibiting substance induces Gro-beta expression in breast cancer cells through a nuclear factor-kappaB-dependent and Smad1-dependent mechanism.
Gupta V; Yeo G; Kawakubo H; Rangnekar V; Ramaswamy P; Hayashida T; MacLaughlin DT; Donahoe PK; Maheswaran S
Cancer Res; 2007 Mar; 67(6):2747-56. PubMed ID: 17363596
[TBL] [Abstract][Full Text] [Related]
14. The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects.
Moserle L; Indraccolo S; Ghisi M; Frasson C; Fortunato E; Canevari S; Miotti S; Tosello V; Zamarchi R; Corradin A; Minuzzo S; Rossi E; Basso G; Amadori A
Cancer Res; 2008 Jul; 68(14):5658-68. PubMed ID: 18632618
[TBL] [Abstract][Full Text] [Related]
15. An update on Mullerian-inhibiting substance: its potential application against ovarian cancer.
Wong RR; Worley MJ; Chung TK; Wong YF
Endocr Relat Cancer; 2014 Jun; 21(3):R227-33. PubMed ID: 24623744
[TBL] [Abstract][Full Text] [Related]
16. Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.
Barbie TU; Barbie DA; MacLaughlin DT; Maheswaran S; Donahoe PK
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15601-6. PubMed ID: 14671316
[TBL] [Abstract][Full Text] [Related]
17. Mullerian inhibiting substance inhibits growth of a human ovarian cancer in nude mice.
Donahoe PK; Fuller AF; Scully RE; Guy SR; Budzik GP
Ann Surg; 1981 Oct; 194(4):472-80. PubMed ID: 6895157
[TBL] [Abstract][Full Text] [Related]
18. Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line.
Fuller AF; Guy S; Budzik GP; Donahoe PK
J Clin Endocrinol Metab; 1982 May; 54(5):1051-5. PubMed ID: 6895900
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic effects of müllerian inhibiting substance (MIS)?
Janssens JP; Noto V; van Tendeloo G; Bonte J; de Loecker W
Anticancer Res; 1988; 8(4):781-4. PubMed ID: 3178166
[TBL] [Abstract][Full Text] [Related]
20. YWK-II protein as a novel G(o)-coupled receptor for Müllerian inhibiting substance in cell survival.
Yin X; Ouyang S; Xu W; Zhang X; Fok KL; Wong HY; Zhang J; Qiu X; Miao S; Chan HC; Wang L
J Cell Sci; 2007 May; 120(Pt 9):1521-8. PubMed ID: 17452623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
